Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Japan Approves Array of Fertility Treatments ahead of Coverage Rollout
March 16, 2022
- MHLW Orders Label Revisions for Brilinta, Ofev, Stocrin
March 16, 2022
- Japan to Ponder Drug Pricing that Ensures Domestic API Production: PM
March 15, 2022
- Japan to Start Booster Program for Ages 12-17 from as Early as April
March 14, 2022
- Japan to Decide on 4th COVID Shot Based on Science, Overseas Reponses: Minister
March 11, 2022
- MHLW to Conduct Follow-Up Survey on Pediatric COVID Vaccinations
March 10, 2022
- Panel Confirms Backing for Alexion’s Bleeding Antidote after Data Integrity Issues
March 10, 2022
- Therapeutic App for Hypertension Now in Line for April Approval
March 10, 2022
- MHLW Drafts Guidelines for Evaluating SaMD Used for Behavioral Modification
March 9, 2022
- MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
March 9, 2022
- MHLW to Fund Development of Kowa’s Ivermectin for COVID-19
March 7, 2022
- MHLW Panel Confirms Positive Cost-Benefit Profile, Efficacy for 9-Valent HPV Vaccine for NIP Inclusion
March 7, 2022
- MHLW Panel Endorses Takeda’s HAE Med and More, Drops AZ’s Asthma Drug
March 4, 2022
- MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts
March 4, 2022
- Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
March 4, 2022
- Outgoing Chair of Unapproved Drug Council Boasts 300 Approvals Achieved to Cut Lag, Urges New Reimbursement Scheme
March 4, 2022
- Alexion’s Bleeding Antidote Up for PAFSC Discussion Again after Data Integrity Issues
March 3, 2022
- Japan Ponders Fourth COVID-19 Vaccine Shot after Autumn
March 3, 2022
- Pfizer’s Paxlovid Listed in MHLW’s COVID-19 Guide
March 3, 2022
- Yervoy Infusion Time Changed for Melanoma: Label Update
March 2, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…